Biotech Values

[xavierprivas]

AKTX Coversin is a dud. AKTX, ACHN, OMER, APLS and RARX are in the complement area competing with ALXN Soliris,
hoping to be the next generation Soliris.

AKTX Coversin data shows it to have less efficacy than Soliris.
In this indication, hematopoietic stem cell transplantation, OMER
drug OMS721 has BTD from FDA. Also has orphan drug status
from both FDA and EMA.

However, I do not own OMER because I believe there are better risk/reward
out there but I would not touch AKTX with a ten foot pole.